Action of nonviral gene delivery vectors on human complement system: low anticomplementary activity of lipoplexes based on lacZ plasmid and phospholipid/oligocation liposomes.
A simple test-system has been developed for the first time in order to detect the ability of effectors (lipoplexes) to activate the complement system in an antibody-independent manner to serve as acceptors of nascent C4b and to inhibit formation of the key enzyme of complement, C3-convertase. The effect of plasmid DNA (pCMV-SPORT-LacZ), negatively charged cardiolipin (CL), neutral phosphatidylcholine (PC) vesicles and their lipoplexes, on the complement system was studied using the method developed. It was revealed that PC vesicles did not affect the complement system, while CL vesicles manifested low activation. The influence of plasmid DNA and its lipoplex based on PC liposomes as well on the complement system was very low. PC/LacZ lipoplex (143 microg/ml) acted on the complement system like 5.36 microg/ml heat aggregated IgG (agg) (the level of no pathological ruptures), whereas CL/LacZ lipoplex (143 microg/ml) acted similar to 10.7 microg/ml IgG (agg). Thus, weak activation of the complement system with CL lipoplex, and even weaker for the PC lipoplex testified to the use of neutral and positively charged lipoplexes preferably in gene therapy protocols. The technique can also be used for testing the influence of injectable gene therapy vectors on the complement system.
Kozlov
L V
LV
G. N. Gabrichevskii Moscow Research Institute of Epidemiology and Microbiology, Russia.
Zhdanov
R I
RI
Guzova
V A
VA
Podobed
V
V
Sviridov
Y V
YV
Bogdanenko
E V
EV
Shvets
V I
VI
Dyabina
S
S
Ermakov
A S
AS
D000818:Animals; D002308:Cardiolipins / Q000276:immunology / Q000494:pharmacology; D003181:Complement C4 / Q000187:drug effects; D003165:Complement System Proteins / Q000187:drug effects*; D018014:Gene Transfer Techniques / Q000592:standards*; D005822:Genetic Vectors / Q000276:immunology / Q000494:pharmacology*; D006168:Guinea Pigs; D006461:Hemolysis / Q000187:drug effects / Q000276:immunology; D006801:Humans; D008081:Liposomes / Q000276:immunology / Q000494:pharmacology; D010713:Phosphatidylcholines / Q000276:immunology / Q000494:pharmacology; D010957:Plasmids / Q000276:immunology / Q000494:pharmacology; D012756:Sheep
D002308:Cardiolipins; D003181:Complement C4; D008081:Liposomes; D010713:Phosphatidylcholines; D003165:Complement System Proteins